Überblick über verschiedene temporäre mechanische Kreislaufunterstützungssysteme

P. Lanmüller, S. Ott, C. Starck, E. Potapov, D. Lewin

1. McDonagh TA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599–726

2. van Diepen S et al. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation 2017; 136: e232–e68

3. Gonzalez LS & Chaney MA. Intraaortic Balloon Pump Counterpulsation, Part I: History, Technical Aspects, Physiologic Effects, Contraindications, Medical Applications/Outcomes. Anesth Analg 2020; 131: 776–91

4. Thiele H et al. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287–96

5. Thiele H et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382: 1638–45

6. Thiele H et al. Intraaortic Balloon Pump in Cardiogenic Shock Complicating Acute Myocardial Infarction: Long-Term 6-Year Outcome of the Randomized IABP-SHOCK II Trial. Circulation 2018

7. Tschope C et al. Mechanical Unloading by Fulminant Myocarditis: LV-IMPELLA, ECMELLA, BI-PELLA, and PROPELLA Concepts. J Cardiovasc Transl Res 2019; 12: 116–23

8. Nersesian G et al. Prediction of survival of patients in cardiogenic shock treated by surgically implanted Impella 5+ short-term left ventricular assist device. Interact Cardiovasc Thorac Surg 2020; 31: 475–82

9. Nersesian G et al. Temporary mechanical circulatory support for refractory heart failure: the German Heart Center Berlin experience. Ann Cardiothorac Surg 2019; 8: 76–83

10. Annamalai SK et al. The Impella Microaxial Flow Catheter Is Safe and Effective for Treatment of Myocarditis Complicated by Cardiogenic Shock: An Analysis From the Global cVAD Registry. J Card Fail 2018; 24: 706–10

11. Lorusso R et al. 2020 EACTS/ELSO/STS/AATS Expert Consensus on Post-Cardiotomy Extracorporeal Life Support in Adult Patients. Ann Thorac Surg 2021; 111: 327–69

12. Cevasco M et al. Left ventricular distension and venting strategies for patients on venoarterial extracorporeal membrane oxygenation. J Thorac Dis 2019; 11: 1676–83

13. Dangas GD et al. Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial). Am J Cardiol 2014; 113: 222–8

14. Katahira S et al. Coronary artery bypass grafting under sole Impella 5.0 support for patients with severely depressed left ventricular function. J Artif Organs 2021

15. Bertoldi LF et al. Weaning from Impella and mobilization of Impella patients. Eur Heart J Suppl 2021; 23: A41–A5

16. Esposito ML et al. Maximum level of mobility with axillary deployment of the Impella 5.0 is associated with improved survival. Int J Artif Organs 2018; 41: 236–9

17. Lauten A et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail 2013; 6: 23–30

18. Karami M et al. Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP/5.0 versus ECMO. Eur Heart J Acute Cardiovasc Care 2020; 9: 164–72

19. Syntila S et al. Comparison of Mechanical Support with Impella or Extracorporeal Life Support in Post-Cardiac Arrest Cardiogenic Shock: A Propensity Scoring Matching Analysis. J Clin Med 2021; 10

20. Cheng JM et al. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 2009; 30: 2102–8

21. Anderson MB et al. Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. J Heart Lung Transplant 2015; 34: 1549–60

22. Pieri M & Pappalardo F. Impella RP in the Treatment of Right Ventricular Failure: What We Know and Where We Go. J Cardiothorac Vasc Anesth 2018; 32: 2339–43

23. Belohlavek J et al. Left ventricular unloading and the role of ECpella. Eur Heart J Suppl 2021; 23: A27–A34

24. Donker DW et al. Right-Left Ventricular Interaction in Left-Sided Heart Failure With and Without Venoarterial Extracorporeal Membrane Oxygenation Support-A Simulation Study. ASAIO J 2021; 67: 297–305

25. Cheng R et al. Lack of Survival Benefit Found With Use of Intraaortic Balloon Pump in Extracorporeal Membrane Oxygenation: A Pooled Experience of 1517 Patients. J Invasive Cardiol 2015; 27: 453–8

26. Ott S et al. Management of increased systemic flow requirements in patients with left ventricular assist devices. Ann Cardiothorac Surg 2021; 10: 399–401

27. Le Gall A et al. Veno-arterial-ECMO in the intensive care unit: From technical aspects to clinical practice. Anaesth Crit Care Pain Med 2018; 37: 259–68

28. Millar JE et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care 2016; 20: 387

29. Lo Coco V et al. Clinical complications during veno-arterial extracorporeal membrane oxigenation in post-cardiotomy and non post-cardiotomy shock: still the achille's heel. J Thorac Dis 2018; 10: 6993–7004

30. Montagner M et al. Single arterial access ECMELLA: A new concept and step-by-step procedure. Multimed Man Cardiothorac Surg 2021; 2021: 10

31. Philipp A et al. First experience with the ultra compact mobile extracorporeal membrane oxygenation system Cardiohelp in interhospital transport. Interact Cardiovasc Thorac Surg 2011; 12: 978–81

32. Mehlhorn U et al. LIFEBRIDGE: a portable, modular, rapidly available "plug-and-play" mechanical circulatory support system. Ann Thorac Surg 2005; 80: 1887–92

33. John R et al. Outcomes of a multicenter trial of the Levitronix CentriMag ventricular assist system for short-term circulatory support. J Thorac Cardiovasc Surg 2011; 141: 932–9

34. Bhama JK et al. Clinical experience using the Levitronix CentriMag system for temporary right ventricular mechanical circulatory support. J Heart Lung Transplant 2009; 28: 971–6

35. John R et al. Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg 2007; 134: 351–8

Die Vergangenheit und die Zukunft der dauerhaften mechanischen Kreislaufunterstützung

D. Lewin, F. Ka□fmann, V. Falk, E. Potapov

1. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599–726
2. DeBakey ME. Left ventricular bypass pump for cardiac assistance. Clinical experience. Am J Cardiol 1971; 27: 3–11
3. Cooley DA et al. Orthotopic cardiac prosthesis for two-staged cardiac replacement. Am J Cardiol 1969; 24: 723–30
4. Copeland JG et al. The total artificial heart as a bridge to transplantation. A report of two cases. JAMA 1986; 256: 2991–5
5. Portner PM, et al. Implantable electrical left ventricular assist system: bridge to transplantation and the future. Ann Thorac Surg 1989; 47: 142–50
6. Christoph Birner NF et al. Herzinsuffizienz. In: e.V. DH, ed. Deutscher Herzbericht 2020. Frankfurt am Main: Georg Thieme Verlag KG; 2021: 105–20
7. Molina EJ et al. The Society of Thoracic Surgeons Intermacs 2020 Annual Report. Ann Thorac Surg 2021; 111: 778–92
8. Michelis KC et al. Dynamic Forecasts of Survival for Patients Living With Destination Left Ventricular Assist Devices: Insights From INTERMACS. J Am Heart Assoc 2020; 9:e016203
9. Frazier OH. First use of an untethered, vented electric left ventricular assist device for long-term support. Circulation 1994; 89: 2908–14
10. Rose EA et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435–43
11. Frazier OH. Evolutionary perspective of mechanical circulatory support as a bridge to heart transplantation. J Heart Lung Transplant 2017; 36: 1283–5

12. Potapov EV, et al. Pulsatile flow in patients with a novel nonpulsatile implantable ventricular assist device. Circulation 2000; 102: 183–7

13. Wilhelm MJ et al. Clinical experience with nine patients supported by the continuous flow Debakey VAD. J Heart Lung Transplant 2001; 20: 201

14. Muslem R et al. Acquired coagulopathy in patients with left ventricular assist devices. J Thromb Haemost 2018; 16: 429–40

15. Nascimbene A et al. Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 2016; 127: 3133–41

16. Hetzer R et al. First experiences with a novel magnetically suspended axial flow left ventricular assist device. Eur J Cardiothorac Surg 2004; 25: 964–70

17. Morshuis M et al. DuraHeart magnetically levitated centrifugal left ventricular assist system for advanced heart failure patients. Expert Rev Med Devices 2010; 7: 173–83

18. Larose JA et al. Design concepts and principle of operation of the HeartWare ventricular assist system. ASAIO J 2010; 56: 285–9

19. Ozalp F et al. Four-year outcomes with third-generation centrifugal left ventricular assist devices in an era of restricted transplantation. Eur J Cardiothorac Surg 2014; 46: e35–40

20. Uriel N et al. Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. Circulation 2017; 135: 2003–12

21. Bourque K et al. Design Rationale and Preclinical Evaluation of the HeartMate 3 Left Ventricular Assist System for Hemocompatibility. ASAIO J 2016; 62: 375–83

22. Potapov EV et al. Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices: the EUROMACS analysis. Eur J Cardiothorac Surg 2021

23. Cho SM et al. Cerebrovascular Events in Patients With Centrifugal-Flow Left Ventricular Assist Devices: Propensity Score-Matched Analysis From the Intermacs Registry. Circulation 2021; 144: 763–72

24. Rose EA et al. Artificial circulatory support with textured interior surfaces. A counterintuitive approach to minimizing thromboembolism. Circulation 1994; 90: 87–91

25. Ferrari A et al. A Novel Hybrid Membrane VAD as First Step Toward Hemocompatible Blood Propulsion. Ann Biomed Eng 2021; 49: 716–31

26. Wu X et al. A free-form patterning method enabling endothelialization under dynamic flow. Biomaterials 2021; 273: 120816

27. Cohrs NH et al. A Soft Total Artificial Heart-First Concept Evaluation on a Hybrid Mock Circulation. Artif Organs 2017; 41: 948–58

28. Latremouille C et al. A bioprosthetic total artificial heart for end-stage heart failure: Results from a pilot study. J Heart Lung Transplant 2018; 37: 33–7

29. Martinolli M et al. Extended finite element method for fluid-structure interaction in wave membrane blood pump. Int J Numer Method Biomed Eng 2021; 37: e3467

30. Martinolli M et al. Computational Fluid-Structure Interaction Study of a New Wave Membrane Blood Pump. Cardiovasc Eng Technol 2021

31. Argiriou M et al. Right heart failure post left ventricular assist device implantation. J Thorac Dis 2014; 6 Suppl 1: 52–9

32. Torregrossa G et al. SynCardia: the total artificial heart. Ann Cardiothorac Surg 2014; 3: 612–20

33. Potapov EV et al. Biventricular support using 2 HeartMate 3 pumps. J Heart Lung Transplant 2016; 35: 1268–70

34. Eulert-Grehn JJ et al. Two implantable continuous-flow ventricular assist devices in a biventricular configuration: technique and results. Interact Cardiovasc Thorac Surg 2018; 27: 938–42

35. Loforte A et al. Temporary right ventricular mechanical support in high-risk left ventricular assist device recipients versus permanent biventricular or total artificial heart support. Artif Organs 2013; 37: 523–30

36. Dandel M et al. Left ventricular vs. biventricular mechanical support: Decision making and strategies for avoidance of right heart failure after left ventricular assist device implantation. Int J Cardiol 2015; 198: 241–50

37. VanderPluym CJ et al. Outcomes following implantation of mechanical circulatory support in adults with congenital heart disease: An analysis of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). J Heart Lung Transplant 2018; 37: 89–99

38. Vierecke et al. Results of primary biventricular support: an analysis of data from the EUROMACS registry. Eur J Cardiothorac Surg 2019

39. Netuka I et al. First Clinical Experience With the Pressure Sensor-Based Autoregulation of Blood Flow in an Artificial Heart. ASAIO J 2021; 67: 1100–8

40. Abraham WT et al. Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. ESC Heart Fail 2021; 8: 3472–82

41. Dual SA et al. Continuous Heart Volume Monitoring by Fully Implantable Soft Strain Sensor. Adv Healthc Mater 2020; 9:e2000855

42. Pae WE et al. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant 2007; 26: 219–29

43. Dowling RD et al. Initial experience with the AbioCor implantable replacement heart system. J Thorac Cardiovasc Surg 2004; 127: 131–41

44. Pya Y et al. First human use of a wireless coplanar energy transfer coupled with a continuous-flow left ventricular assist device. J Heart Lung Transplant 2019; 38: 339–43

45. Escher A et al. A Cavopulmonary Assist Device for Long-Term Therapy of Fontan Patients. Semin Thorac Cardiovasc Surg 2021

46. Eid A et al. 5G as a wireless power grid. Sci Rep 2021; 11: 636

47. Kim YJ et al. NiCo2S4 Bi-metal Sulfide Coating on LiNi0.6Co0.2Mn0.2O2 Cathode for High-Performance All-Solid-State Lithium Batteries. ACS Omega 2021; 6: 6824–35

48. Tan DHSet al. Carbon-free high-loading silicon anodes enabled by sulfide solid electrolytes. Science 2021; 373: 1494–9

Indikationen zur Behandlung des kardiogenen Schocks mittels temporärer mechanischer Kreislaufunterstützung

G. Nersesian, P. Lanmüller, F. Spillmann, C. Starck, F. Schönrath, E. Potapov, S. Ott

1. Chioncel O et al. Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2020; 22(8): 1315–41
2. Baran DA et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019. Catheter Cardiovasc Interv 2019; 94(1): 29–37
3. Molina EJ et al. The Society of Thoracic Surgeons Intermacs 2020 Annual Report. Ann Thorac Surg 2021; 111(3): 778–92
4. McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2021; 42(36): 3599–726
5. Tehrani BN et al. Standardized Team-Based Care for Cardiogenic Shock. J Am Coll Cardiol 2019; 73(13): 1659–69
6. Basir MB et al. Improved Outcomes Associated with the use of Shock Protocols: Updates from the National Cardiogenic Shock Initiative. Catheter Cardiovasc Interv 2019; 93(7): 1173–83
7. Tehrani BN et al. A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock. JACC Heart Fail 2020; 8(11): 879–91
8. Squiers JJ et al. Contemporary extracorporeal membrane oxygenation therapy in adults: Fundamental principles and systematic review of the evidence. J Thorac Cardiovasc Surg 2016; 152(1): 20–32
9. Lemor A et al. Impella Versus Extracorporeal Membrane Oxygenation for Acute Myocardial Infarction Cardiogenic Shock. Cardiovasc Revasc Med 2020; 21(12): 1465–71
10. Pozzi M et al. Extracorporeal life support in the multidisciplinary management of cardiogenic shock complicating acute myocardial infarction. Catheter Cardiovasc Interv 2020; 95(3): e71–e77
11. Muller G et al. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction with cardiogenic shock. Intensive Care Med 2016;42(3): 370–78
12. Weber DM et al. Principles of Impella Cardiac Support. 2009
13. Wernly B et al. Impella in Cardiogenic Shock: Is it Time to Hit the Break? Shock 2021; 55(5): 693–94
14. Seyfarth M et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008; 52(19): 1584–8

15. Manzo-Silberman S et al. Percutaneous left ventricular assistance in post cardiac arrest shock: comparison of intra aortic blood pump and IMPELLA Recover LP2.5. Resuscitation 2013; 84(5): 609–15

16. Ouweneel DM et al. Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump in Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol 2017; 69(3): 278–87

17. Pieri M et al. The role of different mechanical circulatory support devices and their timing of implantation on myocardial damage and mid-term recovery in acute myocardial infarction related cardiogenic shock. J Interv Cardiol 2018; 31(6): 717–24

18. Batsides G et al. Outcomes of Impella 5.0 in Cardiogenic Shock: A Systematic Review and Meta-analysis. Innovations (Phila) 2018; 13(4): 254–60

19. Nersesian G et al. Prediction of survival of patients in cardiogenic shock treated by surgically implanted Impella 5+ short-term left ventricular assist device. Interact Cardiovasc Thorac Surg 2020; 31(4): 475–82

20. Russo JJ et al. Left Ventricular Unloading During Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock. J Am Coll Cardiol 2019; 73(6): 654–62

21. Al-Fares AA et al. Optimal Strategy and Timing of Left Ventricular Venting During Veno-Arterial Extracorporeal Life Support for Adults in Cardiogenic Shock: A Systematic Review and Meta-Analysis. Circ Heart Fail 2019; 12(11): e006486

22. Li Y et al. Effect of an intra-aortic balloon pump with venoarterial extracorporeal membrane oxygenation on mortality of patients with cardiogenic shock: a systematic review and meta-analysis†. Eur J Cardiothorac Surg 2019; 55(3): 395–404

23. Schrage B et al. Left Ventricular Unloading Is Associated With Lower Mortality in Patients With Cardiogenic Shock Treated With Venoarterial Extracorporeal Membrane Oxygenation: Results From an International, Multicenter Cohort Study. Circulation 2020; 142(22): 2095–106

24. Ott S et al. Management of increased systemic flow requirements in patients with left ventricular assist devices. Ann Cardiothorac Surg 2021; 10(3): 399–401

25. Eulert-Grehn JJ et al. ECMELLA 2.0 – Single arterial access technique for a staged approach in cardiogenic shock. Ann Thorac Surg 2020

26. Gaies MG et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med 2010; 11(2): 234–8

27. Abrams D et al. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol 2014; 63(25 Pt A): 2769–78

28. Jayaraman AL et al. Cannulation strategies in adult veno-arterial and veno-venous extracorporeal membrane oxygenation: Techniques, limitations, and special considerations. Ann Card Anaesth 2017;20(Supplement):S11–s18

Dauerhafte ventrikuläre □nterstützungstherapie – ventricular assist device therapy

I.A. J□st, J. M□lzer, C. Hörmandinger, F. Schönrath

1. Braunwald E et al. The war against heart failure: the Lancet lecture. Lancet 2015; 385: 812–24

2. Mamas MA et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail 2017; 19(9): 1095–104

3. De By TMMH et al. The European registry for patients with mechanical circulatory support (EUROMACS) of the European association for cardio-thoracic surgery (EACTS): Second report. Eur J Cardiothorac Surg 2018; 53: 309–16

4. McDonagh TA et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36): 3599–726

5. Crespo-Leiro MG et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20: 1505–35

6. Stevenson LW et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28(6): 535–41

7. Kirklin JK et al. Eighth annual intermacs report: special focus on framing the impact of adverse events. J Heart Lung Transplant 2017; 36: 1080–86

8. Boruah et al. left ventricular assist device: what the internist needs to know. A review of the literature. Cureus 2019; 11: e4399

9. Rose EA et al. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure (RE-MATCH) Study group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435–43

10. Kirklin JK et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant 2014; 33: 555

11. Jakovljevic DG et al. Left Ventricular Assist Device as a Bridge to Recovery for Patients With Advanced Heart Failure. J Am Coll Cardiol 2017; 69: 1924

12. Schnettler JK et al. Safety of contemporary heart failure therapy in patients with continuous-flow left ventricular assist devices. J Card Fail 2021; 27(12): 1328–36

13. Birks EJ et al. Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study. Circulation 2011; 123: 381

14. Pae WE et al. Does total implantability reduce infection with the use of a left ventricular assist device? The LionHeart experience in Europe. J Heart Lung Transplant 2007; 26(3): 219–29

15. Rogers JG et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID trial. J Am Coll Cardiol 2007; 50(8): 741–7

16. Slaughter et al. Advanced heart failure treated with continuous-flow left ventricular assist devices. N Engl J Med 2009; 361: 2241–51

17. Estep JD et al. Risk Assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: results from the ROADMAP study. J Am Coll Cardiol 2015; 66(16): 1747–61

18. Starling RC et al. Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients:the ROADMAP study 2-year results. JACC Heart Fail 2017; 5(7): 518–27

19. Aaronson KD et al. use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012; 125: 3191–200

20. Rogers JG et al. Intrapericardial left ventricular assist device for advanced heart failure. N Engl J Med 2017; 376: 451–60

21. Mehra MR et al. Primay results of long-term outcomes in the MOMENTUM-3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail 221; 23(8): 1392–400

22. Khush KK et al. The International Thoracic Organ Transplant Registry of the International Society of Heart and Lung Transplantation: 37th adult heart transplantation report-2020; focus on deceased donor characteristics. J Heart Lung Transplant 2020; 39(10): 1003–15

23. Molina EJ et al. The society of thoracic surgeons Intermacs 2020 annual report. Ann Thorac Surg 2021; 111(3): 778–92

24. Kormos RL et al. right ventricular failure in patients with the HeartMateII continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 2010; 139: 1316–24

Patienten mit einem linksventrikulären □nterstützungssystem – Besonderheiten in der Patientenversorgung und im Alltag

J. M□lzer, I. A. J□st, F. Schönrath

1. Willemsen et al. Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation von Patienten mit einem Herzunterstützungssystem (VAD - ventricular assist device). Clinical research in cardiology 2016; 11(Suppl1): 2–49

2. Bobenko A et al. Exercise training in patients with a left ventricular assist device (Ex-VAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial. Eur J Heart Fail 2019; (9): 1152–59

3. Cho SM et al. Understanding risk factors and predictors for stroke subtypes in the ENDURANCE trials. J Heart Lung Transplant 2020; 39(7): 639–47

4. Feldman D et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant: Off Publ Int Soc Heart Transplant 2013; 32(2): 157–87

5. Li, Song et al. “Accuracy of Doppler blood pressure measurement in continuous-flow left ventricular assist device patients.” ESC heart failure 2019; (6,4): 793–98

6. Schlöglhofer T et al. International Normalized Ratio Test Frequency in Left Ventricular Assist Device Patients Affects Anticoagulation Quality and Adverse Events. ASAIO J 2021 ; 67(2): 157–62

7. Gummert, Jan F et al. Permanent implantierbare Herzunterstützungssysteme. Permanent implantable cardiac support systems. Dtsch Arztebl Int 2019; 116: 843–8

8. Stainback RF et al. American Society of Echocardiography. Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr 2015; 28(8): 853–909

9. Knierim J et al. Outcomes from a recovery protocol for patients with continuous-flow left ventricular assist devices. J Heart Lung Transplant 2019; 38(4): 440–48

10. Vakil K et al. Implantable Cardioverter-Defibrillator Use in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis. JACC Heart Fail 2016; 4(10): 772–79

11. Alvarez PA et al. Implantable Cardioverter Defibrillators in Patients With Continuous Flow Left Ventricular Assist Devices: Utilization Patterns, Related Procedures, and Complications. J Am Heart Assoc 2019; 8(14): e011813

12. Tehrani DM et al. Unclear Benefit of Cardiac Resynchronization Therapy in Patients with Implanted Left Ventricular Assist Devices. ASAIO J 2019; 65(4): e43

13. Veenis JF & Brugts JJ. Remote monitoring for better management of LVAD patients: the potential benefits of CardioMEMS. Gen Thorac Cardiovasc Surg 2020; 68(3): 209–18

14. Kusne S et al. An ISHLT consensus document for prevention and management strategies for mechanical circulatory support infection. J Heart Lung Transplant 2017; 36(10): 1137–53

15. Bernhardt AM et al. Driveline Expert STagINg and carE DESTINE study group, a Ventricular Assist Device Driveline Infection Study Group. Prevention and early treatment of driveline infections in ventricular assist device patients – The DESTINE staging proposal and the first standard of care protocol. J Crit Care 2020; 56: 106–12

16. Hanke JS et al. Driving After Left Ventricular Assist Device Implantation. Artif Organs 2018; 42(7): 695–99

17. Hanke JS et al. Flying after left ventricular assist device implantation. Artif Organs 2021; 45(3): 230–35

18. Mehra MR et al. MOMENTUM 3 Investigators. A Fully Magnetically Levitated Left Ventricular Assist Device – Final Report. N Engl J Med 2019; 380(17): 1618–27

19. Brouwers C et al. Psychological distress in patients with a left ventricular assist device and their partners: an exploratory study. Eur J Cardiovasc Nurs 2015; 14(1): 53–62

20. Strangl F et al. Assessing palliative care need in left ventricular assist device patients and heart transplant recipients. Interact Cardiovasc Thorac Surg 2020; 31(6): 874–80

21. Fendler TJ et al. Team-based Palliative and End-of-life Care for Heart Failure. Heart Fail Clin 2015; 11(3): 479–98

22. Pak ES et al. Ethical Challenges in Care of Patients on Mechanical Circulatory Support at End-of-Life. Curr Heart Fail Rep 2020; 17(4): 153–60

Temporäre mechanische Kreislaufunterstützung auf der Intensivstation – Management, Komplikationen und Weaning (CME)

S. Ott, G. Nersesian, F. Spillmann, C. Starck, F. Schönrath, E. Potapov, P. Lanmüller

1. Crespo-Leiro MG et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20(11): 1505–35

2. Subramaniam AV et al. Complications of Temporary Percutaneous Mechanical Circulatory Support for Cardiogenic Shock: An Appraisal of Contemporary Literature. Cardiol Ther 2019; 8(2): 211–28

3. Moghaddam N et al. Cardiogenic shock teams and centres: a contemporary review of multidisciplinary care for cardiogenic shock. ESC Heart Fail 2021; 8(2): 988–98

4. Kim DH. Mechanical Circulatory Support in Cardiogenic Shock: Shock Team or Bust? Can J Cardiol 2020; 36(2): 197–204

5. Debrunner M et al. Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 2008; 97(5): 298–305

6. Pudil R et al. Inflammatory response to acute myocardial infarction complicated by cardiogenic shock. Acta Medica (Hradec Kralove) 2001; 44(4): 149–51

7. Shpektor A. Cardiogenic shock: the role of inflammation. Acute Card Care 2010; 12(4): 115–8

8. Millar JE et al. The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care 2016; 20(1): 387

9. Notarianni A et al. Mechanical Cardiac Circulatory Support: an Overview of the Challenges for the Anesthetist. Curr Anesthesiol Rep 2021: 1–8

10. Tanaka D et al. What Is the Optimal Blood Pressure on Veno-Arterial Extracorporeal Membrane Oxygenation? Impact of Mean Arterial Pressure on Survival. Asaio j 2019; 65(4): 336–41

11. Lackermair K et al. Outcome of patients treated with extracorporeal life support in cardiogenic shock complicating acute myocardial infarction: 1-year result from the ECLS-Shock study. Clin Res Cardiol 2020

12. Lüsebrink E et al. Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock. Eur Heart J 2020; 41(38): 3753–61

13. Abrams D et al. Extracorporeal membrane oxygenation in cardiopulmonary disease in adults. J Am Coll Cardiol 2014; 63(25 Pt A): 2769–78

14. Douflé G & Ferguson ND. Monitoring during extracorporeal membrane oxygenation. Curr Opin Crit Care 2016; 22(3): 230–8

15. Douflé G et al. Echocardiography for adult patients supported with extracorporeal membrane oxygenation. Crit Care 2015; 19: 326

16. Taylor M & Taylor B. Cardiac ultrasound and extracorporeal life support: the two go together. J Am Soc Echocardiogr 2015; 28(4): A18–9

17. Shaaban-Ali M et al. Clinical and Technical Limitations of Cerebral and Somatic Near-Infrared Spectroscopy as an Oxygenation Monitor. Journal of Cardiothoracic and Vascular Anesthesia 2021; 35(3): 763–79

18. Bembea MM et al. Neuromonitoring During Extracorporeal Membrane Oxygenation: A Systematic Review of the Literature. Pediatr Crit Care Med 2015; 16(6): 558–64

19. Vranken NPA et al. Cerebral and Limb Tissue Oxygenation During Peripheral Venoarterial Extracorporeal Life Support. J Intensive Care Med 2020; 35(2): 179–86

20. Moynihan K et al. Coagulation monitoring correlation with heparin dose in pediatric extracorporeal life support. Perfusion 2017; 32(8): 675–85

21. Beckmann A et al. Position article for the use of extracorporeal life support in adult patients. Eur J Cardiothorac Surg 2011; 40(3): 676–80

22. Burzotta F et al. Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. Int J Cardiol 2015; 201: 684–91

23. Tamura T et al. Acquired von Willebrand syndrome in patients treated with veno-arterial extracorporeal membrane oxygenation. Cardiovasc Interv Ther 2019; 34(4): 358–63

24. Rougé A et al. Argatroban for an alternative anticoagulant in HIT during ECMO. J Intensive Care 2017; 5: 39

25. Sanfilippo F et al. Bivalirudin for Alternative Anticoagulation in Extracorporeal Membrane Oxygenation: A Systematic Review. J Intensive Care Med 2017; 32(5): 312–19

26. Abbasciano RG et al. Blood Transfusion Threshold in Patients Receiving Extracorporeal Membrane Oxygenation Support for Cardiac and Respiratory Failure-A Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth 2021; 35(4): 1192–202

27. Jiritano F et al. Platelets and extra-corporeal membrane oxygenation in adult patients: a systematic review and meta-analysis. Intensive Care Med 2020; 46(6): 1154–69

28. S3-Leitlinie 011/021: Einsatz der extrakorporalen Zirkulation (ECLS / ECMO) bei Herz- und Kreislaufversagen. (https://www.awmf.org/uploads/tx_szleitlinien/011-021l_S3_Einsatz-der-extrakorporalen-Zirkulation-ECLS-ECMO-bei-Herz-Kreislaufversagen_2021-02.pdf).

29. ELSO Guidelines for Adult Respiratory Failure. Extracorporeal Life Support Organization, Version 1.4 August 2017. Ann Arbor, MI, USA. www.elso.org

30. Abrams D et al. Thrombocytopenia and extracorporeal membrane oxygenation in adults with acute respiratory failure: a cohort study. Intensive care medicine 2016; 42(5): 844–52

31. Pichler P et al. [Use of ECMO in adult patients with cardiogenic shock: a position paper of the Austrian Society of Cardiology]. Med Klin Intensivmed Notfmed 2015; 110(6): 407–20

32. Bolliger D et al. Point-of-care coagulation management algorithms during ECMO support: are we there yet? Minerva Anestesiol 2016; 82(9): 1000–9

33. Kasirajan V et al. Risk factors for intracranial hemorrhage in adults on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 1999; 15(4): 508–14

34. Cheng R et al. Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. Ann Thorac Surg 2014; 97(2): 610–6

35. Lorusso R et al. In-Hospital Neurologic Complications in Adult Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation: Results From the Extracorporeal Life Support Organization Registry. Crit Care Med 2016; 44(10): e964–72

36. Barbone A et al. Left ventricle unloading by percutaneous pigtail during extracorporeal membrane oxygenation. Interactive CardioVascular and Thoracic Surgery 2011; 13(3): 293–95

37. Bavaria JE et al. Changes in left ventricular systolic wall stress during biventricular circulatory assistance. Ann Thorac Surg 1988; 45(5): 526–32

38. Lucas SK et al. The harmful effects of ventricular distention during postischemic reperfusion. Ann Thorac Surg 1981; 32(5): 486–94

39. Jayaraman AL et al. Cannulation strategies in adult veno-arterial and veno-venous extracorporeal membrane oxygenation: Techniques, limitations, and special considerations. Ann Card Anaesth 2017; 20(Supplement): S11–s18

40. Murphy DA et al. Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev 2015; 29(2): 90–101

41. Pan KC et al. The meaning of a high plasma free haemoglobin: retrospective review of the prevalence of haemolysis and circuit thrombosis in an adult ECMO centre over 5 years. Perfusion 2016; 31(3): 223–31

42. Rother RP et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. Jama 2005; 293(13): 1653–62

43. Lubnow M et al. Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange--retrospective analysis of 265 cases. PLoS One 2014; 9(12): e112316

44. Lou S et al. Hemolysis in pediatric patients receiving centrifugal-pump extracorporeal membrane oxygenation: prevalence, risk factors, and outcomes. Crit Care Med 2014; 42(5): 1213–20

45. Lyu L et al. Plasma Free Hemoglobin Is a Predictor of Acute Renal Failure During Adult Venous-Arterial Extracorporeal Membrane Oxygenation Support. J Cardiothorac Vasc Anesth 2016; 30(4): 891–5

46. Appelt H et al. Factors associated with hemolysis during extracorporeal membrane oxygenation (ECMO)-Comparison of VA- versus VV ECMO. PLoS One 2020; 15(1): e0227793

47. Magliato KE et al. Biventricular support in patients with profound cardiogenic shock: a single center experience. Asaio j 2003; 49(4): 475–9

48. O'Neill JM et al. Nosocomial infections during extracorporeal membrane oxygenation. Intensive Care Med 2001; 27(8): 1247–53

49. Burket JS et al. Nosocomial infections in adult patients undergoing extracorporeal membrane oxygenation. Clin Infect Dis 1999; 28(4): 828–33

50. Foley PJ et al. Limb ischemia during femoral cannulation for cardiopulmonary support. J Vasc Surg 2010; 52(4): 850–3

51. Yoshimura N et al. A simple technique for the prevention of lower limb ischemia during femoral veno-arterial cardiopulmonary support. J Cardiovasc Surg (Torino) 1996; 37(6): 557–9

52. Basra SS et al. Current status of percutaneous ventricular assist devices for cardiogenic shock. Curr Opin Cardiol 2011; 26(6): 548–54

53. Kim D et al. Echocardiographic Predictors of Successful Extracorporeal Membrane Oxygenation Weaning After Refractory Cardiogenic Shock. J Am Soc Echocardiogr 2021; 34(4): 414–422.e4

54. Aissaoui N et al. Predictors of successful extracorporeal membrane oxygenation (ECMO) weaning after assistance for refractory cardiogenic shock. Intensive Care Med 2011; 37(11): 1738–45

55. Eulert-Grehn JJ et al. ECMELLA 2.0 - Single arterial access technique for a staged approach in cardiogenic shock. Ann Thorac Surg 2020